SYRS - Syros's SY-5609 shows encouraging action in early-stage solid tumor study

Syros Pharmaceuticals (SYRS) has announced initial safety, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) data from dose-escalating part of its Phase 1 trial of SY-5609 in patients with select solid tumors. Data are being presented at the 32nd EORTC-NCI-AACR Symposium.SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity, as well as dose-proportional PK as both a single agent and in combination, minimal accumulation with repeat dosing.The majority of adverse events reported with SY-5609 as a single agent were low grade, and most common AEs were nausea, diarrhea, fatigue, platelet count decrease, and vomiting.Safety profile of SY-5609 in combination with fulvestrant was consistent with that of single-agent SY-5609.Five of the 13 patients treated with single-agent SY-5609 were response evaluable, and of those, three achieved stable disease and two had progressive disease; one of the four patients treated in the combination cohort was response evaluable

For further details see:

Syros's SY-5609 shows encouraging action in early-stage solid tumor study